Endurance Wealth Management’s Matinas BioPharma MTNB Stock Holding History

Endurance Wealth Management’s Portfolio MTNB Stock Details MTNB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-135	Closed	-$9K	–	640
2021 Q3	$9K	Buy	+135	New	+$5.82K	﹤0.01%	538
2021 Q1	–	Sell	-265	Closed	-$18K	–	662
2020 Q4	$18K	Hold	265	–	–	﹤0.01%	433
2020 Q3	$10K	Buy	+265	New	+$10.5K	﹤0.01%	476
2020 Q1	–	Sell	-25	Closed	-$2K	–	578
2019 Q4	$2K	Buy	+25	New	+$1.45K	﹤0.01%	491

Other funds holding MTNB

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SIG

Sargent Investment Group Bethesda, Maryland $759M AUM 28.58% 1-Year Est. Return

CCM

Courage Capital Management Nashville, Tennessee $70.6M AUM 13.29% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

AWA

Arkadios Wealth Advisors Atlanta, Georgia $6.13B AUM 23.41% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

SCA

STALEY CAPITAL ADVISERS Pittsburgh, Pennsylvania $2.36B AUM 23.72% 1-Year Est. Return

Endurance Wealth Management's MTNB Position: Q4 2021 in Review

Endurance Wealth Management sold out of Matinas BioPharma (MTNB) in Q4 2021, closing a stake of 135 shares — an estimated $9K sold.

Endurance Wealth Management first reported a position in MTNB in Q4 2019 and held it in 4 quarters. The position peaked at $18K in Q4 2020. 66 funds tracked by Wall St. Rank hold MTNB as of Q4 2021.

Endurance Wealth Management reported no remaining Matinas BioPharma position as of Q4 2021 after selling out during the quarter.
Endurance Wealth Management sold 135 Matinas BioPharma shares in Q4 2021, an estimated $9K.
Endurance Wealth Management first reported a position in Matinas BioPharma in Q4 2019 and held it in 4 quarters.
Endurance Wealth Management's Matinas BioPharma position peaked at $18K in Q4 2020.
66 funds tracked by Wall St. Rank held Matinas BioPharma as of Q4 2021.

Based on Endurance Wealth Management's 13F filing for Q4 2021, filed 19 Jan 2022.